A Novel Splicing Mutation Alters DSPP Transcription and Leads to Dentinogenesis Imperfecta Type II

Jun Zhang1,2,*, Jiucun Wang2,*, Yanyun Ma2, Weni Du1, Siyang Zhao1, Zuowei Zhang1,3, Xiaojiao Zhang1,3, Yue Liu4, Huasheng Xiao5, Hongyan Wang2, Li Jin2, Jie Liu1,3*

1 Department of Digestive Diseases, Fudan University, Huashan Hospital, Shanghai, China, 2 Ministry of Education (MOE) Key Laboratory of Contemporary Anthropology and State Key Laboratory of Genetic Engineering, School of Life Sciences, Institutes of Biomedical Sciences, Fudan University, Shanghai, China, 3 Department of Immunology, Shanghai Medical School, Institutes of Biomedical Sciences, Fudan University, Shanghai, China, 4 Department of Stomatology, Huashan Hospital, Fudan University, Shanghai, China, 5 National Engineering Center for Biochip Shanghai, Shanghai, China

Abstract

Dentinogenesis imperfecta (DGI) type II is an autosomal dominant disease characterized by a serious disorder in teeth. Mutations of dentin sialophosphoprotein (DSPP) gene were revealed to be the causation of DGI type II (DGI-II). In this study, we identified a novel mutation (NG_011595.1:g.8662T>C, c.135+2T>C) lying in the splice donor site of intron 3 of DSPP gene in a Chinese Han DGI-II pedigree. It was found in all affected subjects but not in unaffected ones or other unrelated healthy controls. The function of the mutant DSPP gene, which was predicted online and subsequently confirmed by in vitro splicing analysis, was the loss of splicing of intron 3, leading to the extended length of DSPP mRNA. For the first time, the functional non-splicing of intron was revealed in a novel DSPP mutation and was considered as the causation of DGI-II. It was also indicated that splicing was of key importance to the function of DSPP and this splice donor site might be a sensitive mutation hot spot. Our findings combined with other reports would facilitate the genetic diagnosis of DGI-II, shed light on its gene therapy and help to finally conquer human diseases.

Introduction

Dentinogenesis imperfecta (DGI), a kind of hereditary dentin defect, causes the teeth of the patients discolored, translucent and even weaker than normal. It is classified into three types. DGI type I (DGI-I) is syndromic and mainly found simultaneously with osteogenesis imperfecta (OI). DGI type II (DGI-II) is more common and inherited in an autosomal dominant manner. Patients with DGI-II exhibit an opalescent hue of their discolored and translucent teeth. The teeth could be shortened approaching to the DEJ, even to the alveolar ridge. Narrow or even obliterated pulp chamber and root canals were shown under X-ray. DGI type III (DGI-III), which was first found in three isolated pedigrees in the United States in 1957, is now considered as a more severe form of DGI-II [1].

By linkage analysis and further sequence scan, the dentin sialophosphoprotein (DSPP) gene was identified to be the key gene associated with DGI, especially type II and type III [1]. DSPP gene is located on chromosome 4q21.3 and encodes the major noncollagenous protein in tooth dentin. Abundant insoluble mutant DSPP and its degradation products (dentin phosphoprotein, DPP and dentin sialoprotein, DSP) expressed by odontoblast cells could be possibly hypothesized to deactivate or indirectly interfere with the metabolism of other proteins in dentin and result in the phenotypes of DGI.

Mutations in the DSPP gene have been revealed and reported to be the principal cause of DGI type II and type III [1–4]. They could be in exons or introns, could affect one single peptide or cause frameshift of the entire following sequence [5]. Most of these mutations were just reported in DGI affected individuals by sequence analysis, but not further functionally confirmed. Functional confirmation of disease-causing or susceptible variations will definitely help in the understanding of the mechanism of the causation or susceptibility and solidify the association.

Results and Discussion

We identified a pedigree with severe DGI-II in Shaanxi, China. From the family tree spanning five generations (Figure 1), the disease was shown to be inherited in an autosomal dominant manner. The proband is a young man, IV 12 in the family tree. He was hospitalized because of dyspepsia. He presented with a severely affected permanent dentition. His all incisor teeth and four first molar teeth exhibited translucent and opalescent hue, color in dark-yellow to amber. The enamel on the occlusal and lingual surfaces was of serious wear. Dental crowns were shortened and globose, approaching to the DEJ, even to the alveolar ridge (Figure 2).

The regions containing exon2, exon3 and intron3 of DSPP gene were sequenced to detect the causative mutation of this pedigree.
Fortunately, a novel mutation in splice donor site of intron 3 (NG_011595.1:g.8662T>C, c.135+2T>C) was discovered in all affected subjects, while in four unaffected individuals and other 105 unrelated healthy controls, this site was in wild type (Figure 3).

Online splicing prediction by SplicePort (http://spliceport.cs.umd.edu) [6] showed that this mutation might change gene splicing by missing the normal splice donor (location: 3660, short sequence: tacaggtatagg, score: 0.938934), which might lead to the loss of splicing of intron 3. As no DSPP transcript was able to be detected in gingiva or peripheral blood sample by RT-PCR, we decided to confirm the function of this causal mutation by in vitro splicing analysis using the vector pLRT which contained the splicing reporter LTR-SD1-SAExon-SD-SA5opt [7,8].

Both wild type and mutant DSPP alleles (1933bp containing whole exon3-intron3-exon4 and partial intron 2 and intron 4)

**Figure 1. The family tree of the pedigree.** The arrow shows the proband IV_{12}.
doi:10.1371/journal.pone.0027982.g001

**Figure 2. Clinical manifestations of the proband IV_{12}.**
doi:10.1371/journal.pone.0027982.g002

**Figure 3. Sequencing raw data of subjects V_{6} (an unaffected member) and V_{8} (an affected member).** The data are from the reverse complementary sequencing with the primer DSPP_New3R. The arrows show the complementary nucleotide of g.8662 site. V_{6} has homozygous A while V_{8} has heterozygous A/G.
doi:10.1371/journal.pone.0027982.g003
were amplified and cloned into splicing vector pLRT to construct the recombinant plasmids. The plasmids together with naïve plLRT were transfected into 293T cells. Twenty-four hours after the transfection, total RNAs were extracted and reverse transcribed to cDNAs. By PCR and subsequent gel electrophoresis, difference in PCR product length was found between the cells transfected with wild type and mutant DSPP alleles. The product of wild type was 190bp in length, while the mutant had a main product of 319bp (Figure 4) indicating the non-splicing of intron 3. The products were further confirmed by sequencing from both strands. The in vitro splicing analysis was replicated by transfecting the plasmids into COS-1 cells. PCR result was the same as that in 293T cells (Figure 4). Thus, the splicing alteration of this mutation (non-splicing of intron 3) was proved. Taken together with the information from the family tree, this autosomal dominant splicing mutation g.8662T>C was indicated to be the causation of DGI-II in this pedigree.

Splicing alteration is an important disease-causing mechanism. It is reported that approximately 15% of human genetic diseases are caused by mutations at or near splice sites [9]. Previous studies have revealed several mutations (g.8658C>T [10,11], g.8661G>A [12], g.8663G>T [5] and g.8663A>G [13]) in or adjacent to this splice donor site to be the causation of DGI-II. However, the function was not confirmed in any of these mutations. Instead, a skip of exon 3 (p.V18_Q45del) was hypothesized. In this study, we identified the novel causative mutation g.8662T>C in this site and for the first time confirmed its function, which was the non-splicing of intron 3. Before that, as to the function of DSPP mutations, only a skip of exon 3 was noticed by [5] offered DSPP single nucleotide mutations as well as the mechanism in DGI pedigrees. The findings would facilitate the genetic diagnosis of DGI through genetic testing, shed light on its gene therapy and help to finally conquer human diseases.

In conclusion, we identified a novel mutation in the splice donor site of DSPP (g.8662T>C), for the first time proved its function in altering gene transcription (non-splicing of intron 3), and concluded it to be the causation of DGI type II in a Chinese Han pedigree.

Materials and Methods

Ethics Statement

This study was approved by the Human Research Review Committee of Huashan Hospital, Fudan University. All participants signed the informed consent forms and all investigations were carried out adhered to the principles in the Declaration of Helsinki.

Subjects

The pedigree was taken notice of in our clinical work. Five generations were included and three generations are living (III to V). 38 family members were visited (III 1∼III 25, IV 1∼IV 16, V 1∼V 9) and 26 DGI-II affected members were discovered (I 1, II 1, II 8, III 1, III 3, III 5, III 6, III 7, III 11, III 23, III 25, IV 3, IV 6, IV 9, IV 10, IV 12, IV 13, IV 16, V 2, V 4, V 7, V 8, consisting of 15 males and 11 females). 5-10mL of peripheral blood sample from each of 20 family members was collected (III 4, III 6, III 11, III 13, IV 1, IV 2, IV 3, IV 6, IV 7, IV 8, IV 9, IV 12, IV 15, IV 16, V 1, V 2, V 4, V 6, V 7, V 8, consisting of 16 affected and four unaffected members). DNAs were then extracted by QIAamp DNA Blood Mini Kit (QIAGEN, Hilden, Germany). At the same time, 105 unrelated healthy subjects were recruited as genomic controls to evaluate the revealed mutations.

Sequence analysis

The genomic regions of interest were amplified by PCR and subsequently analyzed by double strand sequencing to detect the mutations. The PCR and sequencing were performed with the following primers: DSPP-11F: AGTGCTGAGCTGGTGTGATG DSPP-11R: CACAGATATCACATAAGGCCC DSPP-NEW3F: CAAGGCCCTGTAAAGAAAGCCACT DSPP-NEW3R: TCGTTCCAGCTACTTGGAGGTC

The sequencing raw data revealing the novel g.8662T>C mutation was deposited in GenBank (accession number: JN625214). The following primers were used to confirm the mutation in affected and unaffected subjects from the pedigree as well as in the other 105 unrelated healthy controls:

PCR primers: DSPP1933_L: TCTCAGGCACGCCTCCTG TTC, DSPP1933_R: GCCTGCTGGTTGCTTAGATTCC TTT Sequencing primers: F. Re-seq.: TTGGCCAGGTTTCTGCAAGCA, DSPP319_R: TGCTTCACTTCTGCGG

The online splicing adaptor prediction was carried out by SplicePort (http://spliceport.cs.umd.edu). Both wild type and g.8662T>C substituted whole DSPP gene sequences were inputted and the prediction was performed using default settings.

In vitro splicing analysis

The 1933bp DSPP allele containing whole exon3-intron3-exon4 and partial intron 2 and intron 4 was amplified by PCR with the following primers: DSPP1933_L_MunI: CCCCAATTGTCTGGTCACGCCTCCTGTTC and DSPP1933_R_XhoI: GCATCCTGGTGCTTAGATTCCTTTC, DSPP1933_R: GCATCCTGGTGCTTAGATTCCTTTC, DSPP1933_R: GCATCCTGGTGCTTAGATTCCTTTC.
CCGCTCGAGCATCCTGGTGCTTAGATTCCTT. It was then cloned into the EcoR I/Xho I sites of pLRT to construct the recombinant plasmid. The plasmid was transformed into Escherichia coli strain DH5a to amplify and was subsequently extracted for further use.

Human Embryonic Kidney cell line 293T and African green monkey kidney fibroblast-like cell line COS-1 (Cell Resource Center of Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai, China) were used in cell transfection. Twenty-four hours before transfection, 1.0 × 10⁵ cells were plated in each well of a 12-well plate. By adding 3 μL Lipofectamine 2000 (Invitrogen, Carlsbad, United States), 0.6 μg testing plasmid was transfected into the cells according to the manual of Lipofectamine 2000. The medium was changed to full Dulbecco’s Modified Eagle Medium with high glucose (DMEM-h, Invitrogen) after four hours and the cells were harvested after 24 hours. Total RNAs of the cells were extracted by TRI reagent (Sigma-Aldrich, St. Louis, United States) according to the manufacturer’s manual. Reverse transcription were carried out using High Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Foster City, United States). cDNAs were then tested by PCR with the following primers: DSPP319_L: AAAATCATGAATTTGCATCTCC and DSPP319_R: TTCCCTCC-TACTTCTGGCCCAC. The PCR product was evaluated by gel electrophoresis and confirmed by sequencing with the same primers.

Acknowledgments

We thank Dr. Heiner Schaal from Universitaetsklinikum Duesseldorf, Dr. Jung-Wook Kim from Seoul National University, Dr. Mari Ann Kulseth from Oslo University Hospital and Dr. Jose´ Xavier-Neto from InCor - HC FMUSP for offering splicing vectors.

Author Contributions

Conceived and designed the experiments: JZ JW YM HX HW JL. Performed the experiments: JZ YM SZ ZZ XZ. Analyzed the data: JZ WD YL. Contributed reagents/materials/analysis tools: JW HX LJ JL. Wrote the paper: JZ JW SZ.

References

1. Lee SK, Hu JCC, Lee KE, Simmer JP, Kim JW (2008) A Dentin Sialophosphoprotein Mutation That Partially Disrupts a Splice Accepter Site Causes Type II Dentin Dysplasia. Journal of Endodontics 34: 1470–1473.
2. Zhang XQ, Chen LY, Liu JY, Zhao Z, Qiu EJ, et al. (2007) A novel DSPP mutation is associated with type II dentinogenesis imperfecta in a chinese family. Bmc Medical Genetics 8: 52.
3. Lee SK, Lee KE, Jeon D, Lee G, Lee H, et al. (2009) A Novel Mutation in the DSPP Gene Associated with Dentinogenesis Imperfecta Type II. Journal of Dental Research 88(5): 51–55.
4. Wang HY, Hou YN, Cui YX, Huang YF, Shi YC, et al. (2009) A novel splice site mutation in the dentin sialophosphoprotein gene in a Chinese family with dentinogenesis imperfecta type II. Mutation Research-Fundamental and Molecular Mechanisms of Mutagenesis 662: 22–27.
5. McKnight DA, Simmer JP, Hart PS, Hart TC, Fisher LW (2008) Overlapping DSPP Mutations Cause Dentin Dysplasia and Dentinogenesis Imperfecta. Journal of Dental Research 87: 1108–1111.
6. Dogan RI, Goseke L, Wilbur WJ, Mount SM (2007) SplicePort - An interactive splice-site analysis tool. Nucleic Acids Research 35: W285–W291.
7. Hartmann L, Neveling K, Borkens S, Schneider H, Freund M, et al. (2010) Correct mRNA Processing at a Mutant TT Splice Donor in FANCC Ameliorates the Clinical Phenotype in Patients and Is Enhanced by Delivery of Suppressor U1 snRNAs. American Journal of Human Genetics 87: 480–493.
8. Betz R, Theis S, Akta M, Konermann C, Goecke TO, et al. (2010) Comparative in silico analyses and experimental validation of novel splice site and missense mutations in the genes MLH1 and MSH2. Journal of Cancer Research and Clinical Oncology 136: 123–134.
9. Stenson PD, Ball EV, Mort M, Phillips AD, Shiel JA, et al. (2003) Human gene mutation database (HGMD (R)): 2003 update. Human Mutation 21: 577–581.
10. Zhang XH, Zhao J, Li GF, Gao S, Qiu CC, et al. (2001) DSPP mutation in dentinogenesis imperfecta Shields type II. Nature Genetics 27: 151–152.
11. Song YL, Wang CN, Peng B, Ye XQ, Zhao GF, et al. (2006) Phenotypes and genotypes in 2 DGI families with different DSPP mutations. Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontics 102: 360–374.
12. Xiao SX, Yu C, Chou XM, Yuan WJ, Wang Y, et al. (2001) Dentinogenesis imperfecta 1 with or without progressive hearing loss is associated with distinct mutations in DSPP. Nature Genetics 27: 201–204.
13. Bai HH, Agula H, Wu QZ, Zhou WY, Sun YJ, et al. (2010) A novel DSPP mutation causes dentinogenesis imperfecta type II in a large Mongolian family. Bmc Medical Genetics 11.
14. Kim JW, Hu JCC, Lee JI, Moon SK, Kim YJ, et al. (2005) Mutational hot spot in the DSPP gene causing dentinogenesis imperfecta type II. Human Genetics 116: 106–191.